Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 13/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TYK2 | P29597 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15643178 | 0.82 | CSF1R (0.56) | SMN1; SMN2CSF1RKMT2A | |
| SCHEMBL13602308 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL3262016 | 0.78 | TDP1 (0.52) | SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL2950273 | 0.77 | CSF1R (0.81) | CSF1RJAK2 | |
| SCHEMBL2944460 | 0.77 | TERT (0.54) | SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL15643161 | 0.76 | LDLR (0.56) | SMN1; SMN2CSF1RKMT2AALDH1A1 | |
| SCHEMBL10680062 | 0.76 | JAK2 (0.51) | SMN1; SMN2CSF1RTYK2JAK2JAK1 | |
| SCHEMBL18146535 | 0.75 | CSF1R (0.50) | CSF1RKMT2ATYK2JAK2JAK1 | |
| SCHEMBL18146539 | 0.75 | CSF1R (0.50) | CSF1RKMT2ATYK2JAK2JAK1 | |
| SCHEMBL18146537 | 0.75 | CSF1R (0.50) | CSF1RKMT2ATYK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928844-B1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8492404-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | LCK, BTK, IRAK1 | SMN1; SMN2 3830/4885CSF1R 1266/4885KMT2A 346/4885 |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | LCK, BTK, IRAK1 | SMN1; SMN2 3830/4885CSF1R 1266/4885KMT2A 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.